VA
NXTC icon

Verdad Advisers’s NextCure NXTC Stock Holding History

Verdad Advisers’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.7K Buy
60,451
+17,496
+41% +$129K 0.09% 188
2026
Q1 		$459K Buy
+42,955
New +$525K 0.52% 72

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Verdad Advisers's NXTC Position: Q2 2026 in Review

Verdad Advisers increased its NextCure (NXTC) stake by 41% in Q2 2026, buying an estimated $129K and bringing the position to 60,451 shares worth $96.7K. The position accounts for 0.09% of the portfolio, ranked #188.

Verdad Advisers first reported a position in NXTC in Q1 2026 and has held it in 2 quarters since. The position peaked at $459K in Q1 2026. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Verdad Advisers held 60,451 shares of NextCure worth $96.7K as of Q2 2026.
  • Verdad Advisers bought 17,496 NextCure shares in Q2 2026, an estimated $129K.
  • NextCure made up 0.09% of Verdad Advisers's portfolio in Q2 2026, its #188 holding.
  • Verdad Advisers first reported a position in NextCure in Q1 2026 and has held it in 2 quarters since.
  • Verdad Advisers's NextCure position peaked at $459K in Q1 2026.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.